Merck Stops Phase 3 Trial of Verubecestat in Early Alzheimer’s Patients Amid Concerns Over Benefit

Merck Stops Phase 3 Trial of Verubecestat in Early Alzheimer’s Patients Amid Concerns Over Benefit
In another blow to hopes for an effective Alzheimer’s treatment, Merck announced that it is stopping its Phase 3 clinical study testing verubecestat (MK-8931) in patients with early stage disease. No specific reason was given, but lack of effectiveness in data compiled to date is a likely cause. The decision follows a cease-trial recommendation by an external Data

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *